TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07646613: Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Tr

Sponsor: Aspeya, Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 108 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$2,754,800

Rescue Site Savings

+$1,823,600

Unlock Full NCT07646613 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07646613 Rescue Dossier →